课题基金 / 基金详情

项目摘要

项目成果

SUSAN L KOLETAR的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (adapted from the application's abstract): The Ohio State University AIDS Clinical Trials Unit (ACTU) proposes to collaborate with the Adult ACTG Coordinating and Research Operations Center (CORC) that has identified Robert T. Schooley, M.D., from the University of Colorado as Group Leader. The Ohio State University ACTU proposes to participate in the discovery and development of therapies to improve the quality and duration of life of Human Immunodeficiency Virus (HIV)-infected individuals. The proposed cadre of investigators are from multiple disciplines including infections diseases, virology, immunology, nursing, oncology, neurology, gynecology and clinical pharmacology. They have conducted single- and multi-center HIV/AIDS clinical trials and have established multi-disciplinary collaborations to participate in the AACTG scientific agenda. There are nursing, pharmacy, social work, data management and outreach personnel proposed to: recruit and screen potential patients including women and minorities; implement clinical research protocols; perform protocol required assessments; dispense investigational agents and appropriately document clinical events; and meet all data reporting requirements. There are certified laboratory facilities proposed to conduct or obtain virologic, immunologic and pharmacologic assays in support of AACTG clinical trials with appropriate internal quality controls. There are clinical facilities proposed, including a dedicated Infectious Diseases inpatient service, a full-time outpatient clinic with an ACTU pharmacy and a General Clinical Research Center to execute protocols and provide clinical care in an integrated fashion.
期刊论文(64)
专著(0)
科研奖励(0)
会议论文
A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 x 106 /l.
一项关于 CD4 细胞计数增加至 > 200 x 106 /l 后停止原发性和继发性卡氏肺孢子虫肺炎预防的前瞻性研究。
DOI: 10.1097/00002030-200108170-00008
发表时间: 2001
期刊: AIDS (London, England)
影响因子: --
作者: [Koletar,SL, Heald,AE, Finkelstein,D, Hafner,R, Currier,JS, McCutchan,JA, Vallee,M, Torriani,FJ, Powderly,WG, Fass,RJ, Murphy,RL, ACTG888StudyTeam]
通讯作者: ACTG888StudyTeam
Patient appraisal of mandarin orange didanosine: implications for adherence and well-being.
柑橘去羟肌苷的患者评价:对依从性和健康的影响。
DOI: 10.1016/s1055-3290(06)60230-6
发表时间: 1999
期刊: The Journal of the Association of Nurses in AIDS Care : JANAC.
影响因子: --
作者: [Reynolds,NR, Neidig,JL, Brashers,DE]
通讯作者: Brashers,DE
Kinins as mediators of intestinal secretion.
激肽作为肠道分泌的介质。
DOI: 10.1152/ajpgi.1989.256.1.g1
发表时间: 1989
期刊: The American journal of physiology
影响因子: --
作者: [Gaginella,TS, Kachur,JF]
通讯作者: Kachur,JF
Circulating human immunodeficiency virus (HIV) p24 antigen-positive lymphocytes: a flow cytometric measure of HIV infection.
循环人类免疫缺陷病毒 (HIV) p24 抗原阳性淋巴细胞:HIV 感染的流式细胞术测量。
DOI: 10.1093/infdis/162.5.1018
发表时间: 1990
期刊: The Journal of infectious diseases
影响因子: --
作者: [Ohlsson-Wilhelm,BM, Cory,JM, Kessler,HA, Eyster,ME, Rapp,F, Landay,A]
通讯作者: Landay,A
42
    Pitt-Ohio State Clinical Trials Unit Administrative Supplement
    LOPINAVIR/RITONAVIR PHARMACOKINETICS IN HIV-1
    • 批准号:
      7625455
    • 项目类别:
    • 资助金额:
      $0.19万
    • 财政年份:
      2007
    • 负责人:
      SUSAN L KOLETAR
    • 依托单位:
    PItt-Ohio State-Georgetown Clinical Trials Unit
    SAFETY, TOLERABILITY, AND PHARMACOKINETIC INTERACTIONS OF ATAZANAVIR
    • 批准号:
      7718628
    • 项目类别:
    • 资助金额:
      $0.7万
    • 财政年份:
      2007
    • 负责人:
      SUSAN L KOLETAR
    • 依托单位: